Skeptic's Lab
APOE4: the 'Alzheimer's gene', and what that phrase gets wrong
It is the most anxiety-laden result in consumer genetics, and the place where careful framing matters most. APOE4 raises risk. It does not hand down a sentence.
The claim. APOE4 is 'the Alzheimer's gene'. If you carry it you will get Alzheimer's, there is nothing you can do, so it is better not to know.
Verdict. APOE4 is the strongest common genetic risk factor for late-onset Alzheimer's, but it is a risk factor, not a diagnosis or a destiny. Many carriers never develop the disease, and many people with Alzheimer's carry no APOE4 at all.
APOE comes in three common versions, e2, e3 and e4, set by two variants (rs429358 and rs7412). The e4 version raises the risk of late-onset Alzheimer's, more so with two copies, and tends to shift onset earlier. But it changes probability, not certainty: estimates vary by ancestry, sex and age, plenty of e4 carriers never develop dementia, and plenty of people with Alzheimer's have no e4.
What APOE actually is
APOE encodes a protein that carries lipids and influences how the brain clears amyloid. The three common alleles, e2, e3 and e4, are defined by the combination of two SNPs, rs429358 and rs7412. e3 is the common baseline, e4 is the risk-raising version, and e2 is associated with lower risk. The link between e4 and late-onset Alzheimer's is one of the best-replicated findings in the genetics of common disease.
Risk is not destiny
Carrying one e4 raises lifetime risk of late-onset Alzheimer's relative to the common e3/e3 genotype, and two copies raises it further, with risk also depending on age, sex and ancestry. Commonly cited estimates put one copy at roughly a threefold increase and two copies substantially higher, but an odds ratio is a population-level shift in probability, not your personal verdict.
Most single-copy carriers do not develop Alzheimer's, and APOE4 is neither necessary nor sufficient for the disease. It moves the odds; it does not decide the outcome.
Why 'better not to know' is too simple
The 'nothing you can do' half of the claim is weakening. The same vascular and metabolic factors that matter for heart health are increasingly tied to brain health, and knowing your status can inform screening conversations and eligibility for research and prevention trials.
Whether to learn this about yourself is genuinely personal, and some people would rather not. That is exactly why APOE sits behind its own explicit opt-in rather than appearing by default.
How we handle APOE
Because this result is sensitive and easy to misread, APOE is reveal-gated. It is off unless you deliberately choose to see it, and when shown, the risk is framed as a probability, with the uncertainty named, never as a diagnosis.
What Aimosti would (and wouldn't) show you
If, and only if, you opt in, we report your APOE genotype (read from rs429358 and rs7412) with the risk stated as a probability shift, not a diagnosis. It is off by default; you choose whether to see it.
What we won't claim
We won't tell you that APOE4 means you will get Alzheimer's, that a clear result means you won't, or that there is nothing worth doing. We won't surface this sensitive result without your explicit, separate consent.
Bottom line. APOE4 is the strongest common genetic risk factor for late-onset Alzheimer's, but it is a risk factor, not a diagnosis or a destiny. Many carriers never develop the disease, and many people with Alzheimer's carry no APOE4 at all.
Related: APOE (reveal-gated, opt-in). Restated from: MedlinePlus Genetics: APOE gene · dbSNP: rs429358 · dbSNP: rs7412.